{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:34:27Z","timestamp":1789436067167,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"25-26","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.vaccine.2004.02.023","type":"journal-article","created":{"date-parts":[[2004,3,19]],"date-time":"2004-03-19T16:07:14Z","timestamp":1079712434000},"page":"3464-3469","source":"Crossref","is-referenced-by-count":12,"title":["Experimental squalene adjuvant"],"prefix":"10.1016","volume":"22","author":[{"given":"Judit","family":"S\u00fcli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Ben\u0131\u0301\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eli\u00e1\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160tefan","family":"\u0160vr\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ondrejkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"Ondrejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Bajov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.02.023_BIB1","first-page":"227","article-title":"Sur l\u2019augmentation anormale de l\u2019antitoxine chez les chevaux producteurs de serum antidipht\u00e9rique","volume":"101","author":"Ramon","year":"1925","journal-title":"Bull. Soc. Centr. M\u00e9d. V\u00e9t."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB2","first-page":"881","article-title":"The application of adjuvants to veterinary medicine","volume":"57","author":"Vanselow","year":"1987","journal-title":"Vet. Bull."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB3","unstructured":"Krej\u010d\u0131\u0301 J, Toman M, Pinka K, Jur\u00e1k E, Men\u0161\u0131\u0301k P, Pol\u00e1\u010dek R. Achieved informations about anafylactoid reactions of cattle. Brno (Czech Republic): V\u00daVeL; 1988 [in Czech]."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB4","first-page":"149","article-title":"Studies on the adjuvant effect of water-in-oil-in-water (w\/o\/w) emulsion of sesame oil. I. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-in-water emulsion","volume":"48","author":"Kimura","year":"1978","journal-title":"Jpn. J. Exp. Med."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/iai.28.3.937-943.1980","article-title":"Adjuvant activity of a novel metabolisable lipid emulsion with inactivated viral vaccines","volume":"28","author":"Reynolds","year":"1980","journal-title":"Infect. Immun."},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2004.02.023_BIB6","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0264-410X(02)00168-8","article-title":"The global impact of vaccines containing aluminium adjuvants","volume":"20","author":"Clements","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB7","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.4049\/jimmunol.153.9.4029","article-title":"Systemic cytokine profiles in BALB\/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants","volume":"153","author":"Valensi","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB8","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/S0264-410X(98)00080-2","article-title":"Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use","volume":"16","author":"Deliyannis","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2042-7158.1998.tb03298.x","article-title":"Recent advances in vaccine adjuvants for systemic and mucosal administration","volume":"50","author":"O\u2019Hagan","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0264-410X(98)00195-9","article-title":"Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant","volume":"17","author":"Hilgers","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0264-410X(00)00104-3","article-title":"Adjuvant effects of sulfolipo-cyclodextrin in squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle","volume":"19","author":"Romera","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB12","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/S0264-410X(00)00499-0","article-title":"The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine","volume":"19","author":"Podda","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB13","doi-asserted-by":"crossref","unstructured":"Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, van Nest G. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and vaccine approach. New York: Plenum Press; 1995. p. 227\u201396.","DOI":"10.1007\/978-1-4615-1823-5_10"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB14","first-page":"93","article-title":"A new lipoid adjuvant. I. Preparation and observation of its effectiveness","volume":"44","author":"S\u00fcliov\u00e1","year":"1999","journal-title":"Vet. Med. Czech."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB15","first-page":"187","article-title":"The adjuvant activity of fatty esters. The role of acyl chain length and degree of saturation","volume":"44","author":"Bomford","year":"1981","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB16","first-page":"100","article-title":"A new lipoid adjuvant. II. Harmlessness and local reactogenicity","volume":"44","author":"Ben\u0131\u0301\u0161ek","year":"1999","journal-title":"Vet. Med. Czech."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/meth.1999.0832","article-title":"Squalene and squalane emulsions as adjuvants","volume":"19","author":"Allison","year":"1999","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB18","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/15058","article-title":"Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0022-1759(86)90402-3","article-title":"An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell mediated immunity","volume":"95","author":"Allison","year":"1986","journal-title":"J. Immun. Methods"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB20","unstructured":"European Pharmacopoeia. Porcine parvovirus vaccine (inactivated) 2002;4(965):2279\u201380."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB21","unstructured":"Wilbur LA, Aubert MFA. The NIH test for potency. In: Meslin FX, Kaplan M, Koprowski H, editors. Laboratory techniques in rabies. 4th ed. Geneva: WHO; 1996. p. 360\u20138."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB22","first-page":"493","article-title":"Simple method for estimating 50% endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB23","unstructured":"WHO Expert Committee on Rabies. Technical Report Series 8th Report, No. 824. Geneva: WHO; 1992."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB24","first-page":"535","article-title":"A rapid reproducible test for determining rabies neutralizing antibody","volume":"45","author":"Smith","year":"1973","journal-title":"Bull. WHO"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB25","first-page":"225","article-title":"Titration of rabies antibodies by rapid fluorescent focus inhibition test (RFFIT)","volume":"41","author":"Z\u00e1vadov\u00e1","year":"1996","journal-title":"Vet. Med. Czech."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB26","unstructured":"Guide for Care and Use of Laboratory Animals. Statute No. 289\/2003, published by Government of Slovak Republic, 9 July 2003."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB27","doi-asserted-by":"crossref","unstructured":"Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminium and calcium compounds. In: Powell MF, Newman MJ, editors. Vaccine design. New York: Plenum Press; 1995. p. 229\u201348.","DOI":"10.1007\/978-1-4615-1823-5_8"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/030098589403100121","article-title":"Postvaccinal sarcomas in the cat: histology and immunochemistry","volume":"31","author":"Hendrick","year":"1994","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.5326\/15473317-32-2-91","article-title":"Vaccine site associated sarcomas in cats: clinical experience and a laboratory review (1982\u20131993)","volume":"32","author":"Lester","year":"1996","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0022-1759(92)90302-A","article-title":"A comparison of commercially available adjuvants for use in research","volume":"153","author":"Bennett","year":"1992","journal-title":"J. Immun. Methods"},{"key":"10.1016\/j.vaccine.2004.02.023_BIB31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0923-2494(92)80063-Q","article-title":"Syntex adjuvant formulation","volume":"143","author":"Allison","year":"1992","journal-title":"Res. Immunol."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB32","first-page":"417","article-title":"Causes of anaphylactoid reactions in cattle after lipoid drug administration","volume":"37","author":"Toman","year":"1992","journal-title":"Vet. Med. Czech."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1902\/jop.2002.73.2.191","article-title":"Evaluation of pluronic polyols as carriers for grafting materials: study in rat calvaria defects","volume":"73","author":"Fowler","year":"2002","journal-title":"J. Peridontol."},{"key":"10.1016\/j.vaccine.2004.02.023_BIB34","doi-asserted-by":"crossref","unstructured":"Ben\u0131\u0301\u0161ek Z, S\u00fcli J, Eli\u00e1\u0161 D, Lenhardt L, Ondrejkov\u00e1 A, Ondrejka R, \u0160vr\u010dek \u0160, Bajov\u00e1 V. Experimental squalene adjuvant. II. Harmlessness and local reactogenity. Vaccine 2004;22:3470\u20134.","DOI":"10.1016\/j.vaccine.2004.02.024"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04001859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04001859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T04:30:56Z","timestamp":1682656256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04001859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":34,"journal-issue":{"issue":"25-26","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0264410X04001859"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.02.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}